期刊
MABS
卷 5, 期 6, 页码 946-955出版社
LANDES BIOSCIENCE
DOI: 10.4161/mabs.26390
关键词
hepatitis B virus; bispecific antibody; neutralizing activity; steric hindrance; conformational change; endocytosis
资金
- National Natural Science Foundation of China
- National Key Project for Infectious Diseases [2012ZX10002012-009]
- Ministry of Science and Technology of China
- Shanghai Commission of Science and Technology
- Shanghai Leading Academic Discipline Project [B905]
Treatment of chronic hepatitis B virus (HBV) infection with interferon and viral reverse transcriptase inhibitor regimens results in poor viral clearance, loss of response, and emergence of drug-resistant mutant virus strains. These problems continue to drive the development of new therapeutic approaches to combat HBV. Here, we engineered a bispecific antibody using two monoclonal antibodies cloned from hepatitis B surface antigen (HBsAg)-specific memory B cells from recombinant HBsAg-vaccinated healthy volunteers. Next, we evaluated its efficacy in neutralizing HBV in HepaRG cells. This bispecific antibody, denoted as C4D2-BsAb, had superior HBV-neutralizing activity compared with the combination of both parental monoclonal antibodies, possibly through steric hindrance or induction of HBsAg conformational changes. Moreover, C4D2-BsAb has superior endocytotic characteristics into hepatocytes, which inhibits the secretion of HBsAg. These results suggest that the anti-HBsAg bispecific antibody may be an effective treatment method against HBV infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据